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Abstract
Magnetic resonance imaging (MRI) in rectal cancer was 
first investigated in 1999 and has become almost man-
datory in planning rectal cancer treatment. MRI has a 
high accuracy in predicting circumferential resection 
margin involvement and is used to plan neoadjuvant 
therapy. The accuracy of MRI in assessing mesorectal 
lymph nodes remains moderate, as there are no reli-
able criteria to assess nodal involvement. MRI seems to 
be good in assessing peritoneal involvement in upper 
rectal cancer; this however has been assessed in only 
a few studies and needs further research. For low rec-
tal cancers, mesorectum is thin at the level of levator 
ani especially in relation to prostate; so predicting cir-
cumferential resection margin involvement is not easy. 
However high spatial resolution coronal imaging shows 
levator muscles, sphincter complex and intersphinc-
teric plane accurately. This is used to stage low rectal 
tumors and plan plane of surgery (standard surgery, 
intersphincteric resection, Extralevator abdominoperi-
neal resection). While most centres perform MRI post 
chemoradiotherapy, its role in accurate staging post 
neoadjuvant therapy remains debatable. THe role of 
Diffusion weighted MRI post neoadjuvant therapy is 
being evaluated in research settings.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Magnetic resonance imaging in rectal cancer 
is mandatory for a surgeon to plan neoadjuvant ther-
apy. It also helps in planning surgical approach espe-
cially in low rectal cancer.
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INTRODUCTION
Over the last two decades outcomes of  rectal cancer sur-
gery has improved. The principle of  sharp dissection in 
the total mesorectal excision (TME) plane as advocated 
by Bill Heald and implementation of  national training 
programmes have improved outcomes of  rectal cancer 
surgery[1,2]. The German Rectal Cancer Study Group trial 
showed that preoperative long course chemoradiotherapy 
(LCRT) improves 5-year locoregional recurrence rates 
compared with postoperative LCRT in stage T3, T4, or 
node-positive patients and with less toxicity[3].
The success of  pre-operative therapy over post-
operative treatments meant that a technique identifying 
prognostic factors pre-operatively is of  potential benefit 
in modifying the intensity of  pre-operative therapy ac-
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cording to risk of  local or distant failure. Careful staging 
of  rectal tumors results in selective pre-operative treat-
ment strategies aimed at reducing local failure and distant 
failure in high risk patients[4].
In rectal cancer staging, magnetic resonance imaging 
(MRI) has played a crucial role. In this review, we discuss 
in brief  the history and relevance of  rectal MRI through 
a surgeon’s perspective.
RESEARCH
A systematic search of  PubMed, MEDLINE and the 
Cochrane Library databases was performed from January 
1995 to March 2013 using the terms: “MRI and rectal 
cancer” to identify studies investigating role of  MRI in 
rectal cancer surgery. Using the criteria listed above 1231 
articles were identified. After records were screened by 
abstract, 137 articles were eligible for full text evaluation 
and 72 were included in the reference list. This review 
included brief  history of  MRI in rectal cancer with its 
role in staging, selecting patients for neoadjuvant therapy, 
classification rectal cancers and other relevant topics.
History
The first MRI of  human body was performed in 1977. In 
1980 GE built the first high-field whole body MRI scan-
ner. Blomqvist et al[5] in 1999, performed MRI on rectal 
cancer specimens concluded that presence of  tumor free 
lateral resection margin could be predicted by MRI of  
resected specimen when this exceeds 1 mm[5]. However 
it is Brown et al[6] who used thin section MRI imaging to 
identify mesorectal fascia in all patients and accurately 
stage tumors especially T3 tumors. The same group per-
formed MRI in cadaveric sections and in patients before 
they underwent total mesorectal excision surgery to es-
tablish criteria for visualization of  the structures relevant 
to anterior resection of  the rectum[7]. The MERCURY 
(Magnetic Resonance Imaging and Rectal Cancer Euro-
pean Equivalence) Study Group is a multicenter multi-
disciplinary collaboration formed in 2001. This group 
evaluated association between MRI and histopathology in 
measuring depth of  tumour invasion beyond the bowel 
and involvement of  the circumferential resection margin 
(CRM) in rectal cancer specimens[8,9]. Low Rectal Cancer 
study group (LOREC) is undertaking a study with the 
primary aim to reduce rate of  incomplete excision in 
these patients from 30% to less than 10%[10].
Principles of MRI scan
Clinical MRI uses the magnetic properties of  hydrogen 
and its interaction with both a large magnetic field and 
radio waves to produce highly detailed image of  human 
body. By changing parameters on scanner a contrast be-
tween tissues can be obtained. T1 images-water and fluid 
containing tissues dark and fat brighter, basic scan; T2 
images-water and fluid containing tissues bright, fat dark 
suited to show edema; FLAIR sequence-water dark but 
edema bright.
Special MRI: MR imaging of  the rectum may be per-
formed with either an endorectal coil or a phased-array 
surface coil. While endorectal coil gets better resolution 
of  lesion, it is uncomfortable and cannot be used for ste-
nosing lesion and rectosigmoid tumors. Hence standard 
MRI includes images with phased-array body coil only.
Diffusion MRI: Diffusion-weighted MRI (DW-MRI) is 
a functional imaging technique that displays information 
about the extent and direction of  random water motion 
in tissues. Preclinical and clinical data indicate a number 
of  potential roles of  DW-MRI in the characterization of  
malignancy, including determination of  lesion aggressive-
ness and monitoring response to therapy[11-13].
MRI with super paramagnetic iron oxide: In struc-
tures such as lymph nodes, insufficient contrast between 
normal and diseased tissues requires development of  
contrast agents. Super paramagnetic iron oxide (SPIO) 
structure is composed of  ferric iron and ferrous iron 
(coated with a layer of  dextran or other polysaccharide). 
SPIO particles are taken up by phagocytic cells such as 
monocytes, macrophages, and oligodendroglial cells but 
not by tumor cells. This SPIO enhanced MRI to enhance 
nodal resolution is under investigation and has shown 
promising results in rectal cancer[14,15]. Use of  this agent 
in patients who have complete response after LCRT can 
be potentially used to identify patients (no lymph node 
involvement) who may be candidates for local excision 
yPT0/T2[16]. This agent is not FDA approved for rectal 
MRI.
Guidelines to perform MRI rectum
The technique for MRI in rectal cancer has been de-
scribed by Taylor et al[17] (MERCURY study). The clini-
cian provides location of  tumor on rigid sigmoidoscopy. 
There is no need for bowel preparation or intravenous 
contrast. We use 1.5-T system with phased array coil 
with the coil positioned from sacral promontory to 10 
cm below pubic symphysis. Rectal distention with water 
may improve the depiction of  a primary rectal tumor and 
the assessment accuracy of  a perirectal tumor extension, 
but it does not improve the accuracy for determining the 
presence of  regional lymph node involvement[18]. This 
however is not used routinely except selected centres: (1) 
the first series-sagittal, T2-weighted, fast spin echo from 
one pelvic sidewall to other, which locates tumor and re-
lation to peritoneal reflection; (2) the second series- large 
field of  view axial sections whole pelvis; (3) the third 
series-T2 weighted thin slice (3 mm) axial images through 
rectal cancer perpendicular to long axis rectum; and (4) 
for low rectal cancers, high spatial resolution coronal 
imaging to show levator muscles, sphincter complex and 
intersphincteric plane.
There is no need for post contrast MRI. Only T2 
weighted non-fat suppressed sequences in all three 
orthogonal planes to tumor axial, coronal and sagittal 
should be used (Figure 1). The findings on scan are re-
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corded on set proforma, which shows MRI based clas-
sification of  rectal tumors, classification for low rectal 
tumors, tumor regression grades after LCRT on MRI[19].
Normal MRI findings: Anatomy, T2-weighted MR 
imaging sequences are the most suitable for depicting 
the rectal wall anatomy. The rectal wall consists of  three 
different layers that can be recognized at MR imaging. In-
ner hyper-intense layer, which represents the mucosa and 
submucosa (no differentiation is possible between these 
two components); an intermediate hypointense layer, 
which represents the muscularis propria; and an outer hy-
perintense layer, which represents the perirectal fat tissue. 
The mesorectal fascia appears as a thin, hypointense line 
surrounding the hyperintense perirectal fat (Figure 2). At 
the level of  levator ani/prostate mesorectum is thin ante-
riorly and mesorectal fascia is close to muscularis propria, 
so accuracy is low[20]. At the level of  anal canal, even if  
the spatial resolution is low compared with endoanal 
coil imaging, all of  the major anatomic structures (leva-
tor ani muscle, puborectal muscle, internal and external 
anal sphincters, anal canal) can easily be evaluated. CRM 
is considered as closest distance from tumor to MRF 
(mesorectal fascia and around the levator, tumor invading 
the intersphincteric plane or extends to within 1 mm of  
the levator muscle is considered to potentially involve the 
CRM.
Besides normal anatomy, MRI pelvimetry can be used 
to anticipate problems during TME dissection. Kim et 
al[21] analysed factors related to difficult Laparoscopic 
TME (pelvic dissection time). In a prospective study en-
rolling 74 patients, tumor and patient characteristics (in-
cluding pelvic dimensions) were analysed with respect to 
pelvic dissection time. Multivariate analysis showed that 
patients with longer sacral length, narrow intertuberous 
diameter and shallow sacral angle on MRI had longer pel-
vic dissection time but were not associated with increased 
postoperative complications[21]. Also variations in pelvic 
dimensions did not predict the risk of  CRM involvement 
in rectal cancer[22].
MRI rectal cancer
It is mandatory to have location of  tumor on rigid sig-
moidoscopy prior to performing a MRI scan. Location 
of  tumor on MRI and rigid sigmoidoscopy have a 10% 
discrepancy in location, the difference being 3 cm for 
anterior tumors while it is 1.2 cm for posterior tumors[23]. 
For upper rectal cancers, relation to peritoneal reflection 
is looked out for. Mucinous and non--mucinous rectal 
tumors can be differentiated with MR Imaging. Mucinous 
tumors are hetrogenous with intermediate and high SI 
(signal intensity) on T2-weighted FSE (fast spin echo) 
images reflecting the mucin content[24,25] Figure 3.
Staging: Tumor staging and EMD (extramural depth of  
tumor) assessment, There is seldom any dispute about 
Endo anal ultrasonography being more accurate when 
compared to MRI for T1/T2 lesions[26]. A recent meta-
nalysis of  MRI staging of  rectal cancer (T1/T2 vs T3/T4) 
revealed a sensitivity and specificity of  T staging to be 
87% and 75%[27], Table 1. Previous studies have described 
staging failures due to overstaging of  T2 lesions with dif-
ficulty in the distinction of  spiculation in the perirectal 
fat caused by fibrosis alone compared with that caused by 
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Figure 1  Magnetic resonance imaging technique. T2 weighted non-fat sup-
pressed sequence in all three orthogonal planes to tumor axial, coronal, sagittal 
should be used. 
Figure 2  T3 tumor, circumferential resection margin not threatened. T2W 
axial magnetic resonance imaging image shows a mildly hyperintense prolifera-
tive tumor along the right lateral and posterior wall (black arrow). Arrow head 
shows the tumor reaching upto the muscularis with spiculation in the adjacent 
perirectal fat. The white arrows show the mesorectal fascia which is not in-
volved/threatened.
Figure 3  Mucinous adenocarcinoma of rectum. Sagittal T2 weighted MRI 
image showing a circumferential rectal tumour with high signal intensity (arrows) 
characteristic of a mucinous tumor. MRI: Magnetic resonance imaging.
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nodes less than or equal to 5 mm on MRI were involved 
with metastatic disease[31,32]. A suspicious nodebased on 
an irregular border or mixed signal intensity had a superi-
or accuracy with a sensitivity of  85% and a specificity of  
97%[31] (Figure 4). However, these can be subjective with 
inter observer variability. Distance of  involved node to 
CRM is important. If  suspicious nodes are present, one 
to three nodes is stage N1 and four or more is stage N2.
A metanalysis of  MRI staging of  rectal cancer re-
vealed a sensitivity and specificity of  N staging to be 77% 
and 71%[27]. This indicates limitation of  MRI in assessing 
mesorectal lymph nodes, which is exacerbated by the lack 
of  agreement on optimal criteria to assess lymph nodes.
However, high-resolution pelvic MRI was more ac-
curate than PET/CT for the prediction of  regional nodal 
status. Magnetic resonance imaging had a high sensitivity 
and PET/CT had a high specificity for N staging in rectal 
cancer[33].
Mesorectal fascia and CRM: Although the tumour 
stage on MRI is an important prognostic factor, it alone 
may not alter preoperative or operative management. Pre-
diction of  the CRM, by contrast, could be clinically use-
ful to select patients for preoperative radiotherapy. MRI 
prediction of  CRM mesorectal fascia (MRF) with final 
histology was performed by Beets-Tan et al[28]. They con-
cluded that tumour-free margin of  at least 1.0 mm could 
be predicted when the measured distance on MRI was at 
least 5.0 mm, and a margin of  at least 2.0 mm when the 
MRI distance was at least 6.0 mm. Inter observer agree-
ment was better for CRM than for T stage. However 
nodes threatening CRM can were difficult to evaluate.
CRM margin 5 mm or 1 mm: While the original study 
by Beets-tan concluded that MRI prediction of  CRM 
involvement is reliable but suggested the use of  a wider 
threshold on MRI compared to pathology[28]. The MER-
CURY group based their predicted CRM involvement on 
MRI to be less than 1 mm. A prospective study by Taylor 
et al[34] also showed that a cutoff  of  1 mm on MRI could 
be used to predict clear margins with a low positive histo-
logic CRM rate (3.3%)[34].
fibrosis that contains tumor cells[28]. Peritumoral fibrosis 
is represented by spiculation while broad based nodular 
growth is tumor spread.
Although tumor staging with use of  the T compo-
nent of  the TNM classification is the traditional method 
of  prognostically stratifying patients, this approach has 
limitations[26]. The main limitation of  T staging is that T3 
tumors comprise the majority of  rectal cancers seen at 
presentation, and the outcome of  patients with these tu-
mors depends on the depth of  extramural spread.
The maximal extramural depth (EMD) of  tumor 
spread, defined on histopathologic analysis as the dis-
tance from the outer edge of  the longitudinal muscularis-
propria to the outer edge of  the tumor is more related to 
tumor prognosis and preoperative therapy than T stage 
alone. In one of  the largest series published by a Uni-
versity of  Erlangen group, T3 tumors with extramural 
spread of  more than 5 mm were associated with a 5-year 
cancer-specific patient survival rate of  only 54%, but T3 
tumors with 5 mm or less of  extramural spread regard-
less of  whether lymph node involvement was present 
were associated with a 5-year cancer-specific survival rate 
of  greater than 85%. T3 tumors with 5 mm or less of  
extramural spread and pT2 patients showed very similar 
5-year survival rates (both lymph node positive and nega-
tive patient)[29].
In a prospective study of  679 patients with rectal can-
cer, MERCURY group demonstrated EMD invasion to 
be equivalent on MRI and histopathology to a mean dif-
ference of  less than 0.5 mm[9]. Pederson et al[30] evaluated 
168 patients with rectal cancer MRI and histopathological 
examination and felt measurements of  extramural tumor 
spread are more reproducible among different observers 
than are 5 mm distance measurements to the anticipated 
CRM. This EM spread is the basis of  classification of  T3 
tumors on MRI (T3a EMD < 1 mm, T3b 1-5 mm, T3c 
5-15 mm, T4 > 15 mm).
NCCN guidelines recommend neoadjuvant LCRT 
for all T3/T4 tumors irrespective of  CRM involvement. 
However in the United Kingdom, LCRT would be re-
served for only T3 tumors with threatened CRM. How-
ever it can be suggested, that for T3 tumors with EMD 
invasion > 5 mm (bad T3) but with clear CRM can un-
dergo preoperative short course radiotherapy rather than 
surgery alone.
Nodes: Size is not a criteria for lymph node involve-
ment[27]. In fact, one study found that 15% of  lymph 
Figure 4  T1 N+ tumor. T2W axial magnetic resonance image shows two small 
nodes in the mesorectal fat on the left (white arrows) with irregular borders and 
signal intensity similar to primary tumor along left lateral wall (black arrow). 
Table 1  Metanalysis of magnetic resonance imaging staging 
of rectal cancer-Al-Sukhni et al [27]
Sensitivity% (95%CI) Specificity% (95%CI) DOR (95%CI)
T stage 87 (81-92) 75 (68-80) 20.4 (11-37)
N stage 77 (69-84) 71 (59-81)       8.3 (4.6-14.7)
CRM 77 (57-90) 94 (88-97)   56.1 (15-205)
DOR: Diagnostic odds ratio; CI: Confidence interval; CRM: Circumferential 
resection margin. 
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In the MERCURY group study, the accuracy for pre-
dicting the status of  CRM by initial imaging or imaging 
after treatment but before surgery in 408 patients was 
88%. Of  the 408 patients, 311 underwent primary sur-
gery. The accuracy for prediction of  a clear margin was 
91% with a negative predictive value of  93%. This com-
pared with an accuracy of  77% and negative predictive 
value of  98% in patients who had received preoperative 
chemoradiotherapy or long course radiotherapy[8].
A recent meta analysis to assess accuracy of  MRI 
staging rectal cancer based on 21 studies concluded that 
MRI specificity was significantly higher for CRM involve-
ment (94%) than for T category (75%) and lymph nodes 
(71%)[27] Table 2. However MRI can overestimate the 
CRM involvement in low and anterior tumor with the 
risk of  over treating the patients[35,36].
Extramural vascular invasion
Extramural vascular invasion is an important and inde-
pendent prognostic feature that can be readily identified 
on MRI. The morphologic features of  extramural venous 
invasion on baseline T2 weighed MRI range from dis-
crete serpiginous or tubular projections of  intermediate 
signal intensity into perirectal fat following the course 
of  a visible vessel to, in more advanced cases, the vessel 
being expanded by intermediate-signal-intensity tumor 
and having an irregular contour, Figure 5. The degree of  
extramural venous invasion system predicts relapse-free 
survival, with a 3-year relapse-free survival rate of  35% 
for patients with advanced extramural venous invasion, 
compared with 74% for those with no or early extramural 
venous invasion[37].
Pelvic lymph nodes: While lateral pelvic lymph node 
dissection (LPLND) is not performed routinely in United 
Kingdom, this is a good prognostic indicator as evaluated 
as part of  MERCURY study. Patients with rectal cancer 
and suspicious pelvic side-wall lymph nodes (PSW) on 
MRI had significantly worse Disease free survival (DFS) 
that improved with the use of  preoperative therapy. Five-
year DFS was 42% and 70.7% respectively for patients 
with, and without suspicious PSW nodes (P < 0.001), 
but the presence of  suspicious nodes had no impact on 
survival among patients who received preoperative ther-
apy[38]. Based on this, most Mutidisciplinary teams would 
advocate preoperative LCRT for patients with rectal can-
cer and suspicious PSW nodes. While most nodes shrink 
with LCRT, management of  persistent PSW nodes after 
LCRT is not standardized. In South Korea, selective uni-
lateral/bilateral LPLND is performed for persistent PSW 
after LCRT[39]. From a surgeon’s perspective, localization 
of  these lymph nodes by preoperative MRI is important. 
At Yonsei university, between 2007 and 2012, of  1686 
patients who underwent TME for rectal cancer, 92 (5.4%) 
patients underwent TME and LPND (unpublished). This 
however is not evidence based and requires further re-
search.
Peritoneal involvement: Burton et al[40] in a small study 
showed that tumors of  the distal sigmoid, rectosigmoid, 
and upper rectum can be staged accurately using high 
spatial resolution MRI and that those with poor prognos-
tic disease including upper rectal cancer (anterior) may 
benefit from preoperative therapy. However further trials 
regarding this may be worthwhile.
MRI BASED CLASSIFICATION AND 
PLANNING THE SURGICAL PROCEDURES 
FOR LOW RECTAL CANCER
Currently, rectal cancer is classified based on the distance 
from the anal verge (upper, middle and lower). However, 
a selection of  the optimal surgical procedures by tumor 
height is not enough. Low rectal tumors especially those 
treated by abdominoperineal excision (APE), have a high 
rate of  margin involvement when compared with tumors 
elsewhere in the rectum. Correct surgical management 
to minimise this rate of  margin involvement is reliant on 
highly accurate imaging, which can be used to plan the 
Figure 5  T2 tumor coronol views with extramural venous invasion. Coro-
nal T2W magnetic resonance imaging shows a cicumferential tumor in the 
rectum (small arrows) reaching the muscularis with extramural venous invasion 
(long arrow). 
Table 2  Classification of low rectal cancers Shihab et al [41]
Level Tumor height Tumor depth Operative plane






Confined to muscle LAR/intersphincteric 
APE
Beyond muscle LAR/intersphincteric 
APE
Tumor < 1 mm MRF/
levator
Extralevator APE
Tumor extending beyond 
levator
Extralevator APE








Full thickness muscle Extralevator APE
In to intersphincteric plane Extralevator APE
In to external sphincter Extralevator APE
Beyond external sphincter 
into ischiorectal tissue
Pelvic exenteration
APE: Abdominoperineal excision; LAR: Low anterior; MRF: Mesorectal 
fascia. 
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planes of  excision. Two staging systems for low rectal 
cancers have been proposed[17,41] (Tables 2 and 3). Shihab 
et al[42] reported a retrospective analysis of  MRI and his-
topathology data of  33 patients with low rectal cancer. 
They felt defining plane of  surgery preoperatively would 
be the best way to avoid a positive margin[42].
Similarly, based on Taylor classification, positive resec-
tion margins of  patients undergoing APER/Low anterior 
resections were analysed. Of  101 patients with low rectal 
cancers (70 APER, 30 ant resection), positive resection 
margin odds were higher for magnetic resonance Stages 3 
to 4 than Stages 1 to 2 by a factor of  17.7 (P < 0.001)[43]. 
Based on this classification we can plan a tailored pro-
cedure as shown below: Stage 1-TME; Stage 2-TME + 
intersphincteric resection; Stage 3-APER; Stage 4-APER 
or pelvic exenteration.
MRI for radiotherapy planning
CT scan remains a gold tool for planning radiotherapy 
for rectal cancer (conformal radiotherapy using 3 dimen-
sional views). Most Radiation oncologists would also have 
access to MRI views to enable planning i.e., delineation 
of  target volume. Tumour volumes defined on MRI are 
smaller, shorter and more distal from the anal sphincter 
than CT-based volumes. For radiotherapy planning, this 
may result in smaller treatment volumes, which could lead 
to a reduction in dose to organs at risk and facilitate dose 
escalation[44,45]. Co-registration of  the images where MR 
images are used for optimal outlining while retaining the 
CT data for dose calculations is now considered the gold 
standard in prostate cancer radiotherapy[46]. However for 
rectal cancer, further research is required regarding this.
MRI as prognostic factors
Following can be used as a prognostic factors on MRI: (1) 
tumor EMD/T4/CRM; (2) extramural vascular invasion; 
(3) inflammatory reaction; (4) mucinous tumours; (5) pel-
vic lymphnodes; and (6) MRI assessment of  TRG (tumor 
regression grade) and CRM are imaging markers that pre-
dict survival outcomes for good and poor responders[47]. 
Practically it translates in to following.
Good tumor no adjuvant therapy: The preoperative 
identification of  good prognosis tumors using MRI al-
lows stratification of  patients and targeting of  preop-
erative therapy. MRI can also identify T3 rectal cancer 
patients who are likely to have a good outcome with pri-
mary surgery alone[34].
Poor prognostic tumors may benefit from: (1) pre-
operative extrastaging: Adverse features found on rectal 
MRI identify patients at increased risk of  synchronous 
metastatic disease. Hunter et al[48] evaluated the incidence 
of  synchronous metastatic disease on FDG-PET/CT 
and contrast-enhanced multiple-row detector computed 
tomography in MRI-stratified high- and low-risk rectal 
cancers. Incidence of  confirmed distant metastases was 
significantly greater in the MRI high-risk group, with 
20.7% vs the low-risk group, with 4.2% (odds ratio 6.0). 
This group may benefit from additional preoperative 
investigation for synchronous metastases such as FDG-
PET/CT or liver MRI; and (2) trials involving Novel 
therapies such as Neoadjuvant capecitabine and oxali-
platin followed by synchronous chemoradiation and 
total mesorectal excision in magnetic resonance imaging-
defined poor-risk rectal cancer[49].
MRI variation in countries
While there is good evidence supporting the role of  MRI 
in rectal cancer, resource limitations and lack of  National 
guidelines mean many patients with rectal cancer are 
still operated upon without preoperative MRI leading to 
suboptimal results. In United Kingdom in 2005, less than 
50% of  the units studied were able to offer preoperative 
MRI to all of  their rectal cancer cases[50]. This however 
has changed to near 84% in 2012[51]. In an international 
questionnaire regarding use of  MRI in rectal cancer, only 
35% respondents used MRI routinely[52]. In South Korea, 
rectal MRI has been used for local staging since 2005, 
now it is very popular (90%). Furthermore cost of  MRI 
is covered with national insurance system. In our institu-
tion, usually MRI and trans rectal USG are performed 
together for all mid and low rectal cancer patients.
POST LCRT MRI
MRI in rectal cancer is sometimes performed after ra-
diotherapy (MRI 2) to evaluate tumor response and to 
choose alternative forms of  surgery (Figure 6). With re-
gards to MRI 2, there are two schools of  thought.
MRI2 mandatory
MERCURY group believe MRI 2 should be manda-
tory for post treatment staging. This special radiology 
group felt with appropriate training, radiologists were 
able to differentiate tumor and fibrosis and even acel-
lular mucin from cellular mucin on MRI scans. On post 
CRT T2 weighted images areas of  fibrosis have very low 
signal intensity (similar to muscularis propria), whereas 
areas of  residual tumor have intermediate signal intensity 
(similar to baseline tumor). Careful examination of  high-
resolution images enables delineation of  small foci of  
intermediate signal intensity tumor in areas of  low inten-
sity fibrosis. Low intensity spicules in perirectal fat radiat-
ing from residual tumor represent desmoplastic reaction 
whereas advancing tumor has more nodular intermediate 
signal intensity. The guidelines for reporting MRI2 have 
been published by Patel et al[53], Table 4. MRI for restaging 
Table 3  Classification low rectal cancer (Taylor et al [34] 
2008)
Stage
1 Tumor confined to bowel wall, outer muscle intact
2 Tumor occupies muscle coat but does not enter intersphincteric 
plane
3 Tumor enters intersphincteric space or lies within within 1 mm 
of levator muscle
4 Invades external anal sphincter or is 1 mm or beyond levator 
with/without adjacent organ involvement
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has established accuracy of  involvement of  intersphinc-
teric plane[42,43,47]. Another argument on which MRI was 
based was that endoluminal USG cannot differentiate tu-
mor and fibrosis[54,55]. In a study by this group, the nega-
tive predictive value of  CRM for MRI 2 was 98%. In this 
study both posttreatment MRI T staging and posttreat-
ment MRI assessment of  tumor regression grade showed 
statistical correlation with pathologic T stage, which in 
turn was strongly associated with overall and disease-free 
survival as well as local recurrence[56].
As a consequence, reassessment of  MRI scans after 
preoperative therapy has implications for surgical plan-
ning, the timing of  surgery, sphincter preservation[53,56]. 
Patients with CRM positivity on MRI 2 may require exci-
sion of  adjacent organs (exenteration). While it has been 
suggested development of  further preoperative treat-
ments for radiologically identified poor responders and 
deferral of  surgery for good responders, this can happen 
only in context of  a trial. Phase Ⅱ trials are currently 
evaluating the safety of  deferring surgical resection in 
patients with a good response as shown on MRI[57]. How-
ever there are drawbacks, while MRI 2 has an negative 
predictive value of  98% for CRM, its specificity for CRM 
was 73% (compared to 92% for MRI 1)[8]. This would 
mean, excision performed based on MRI2, chances of  
involved margin would be less, but at the same time, 
you would be likely to overtreat and excise outside TME 
plane/exenteration. Sphincter preservation (ISR) would 
also be less likely.
MRI2 optional/unnecessary
MRI accuracy is poor after LCRT, T stage (43%), N stage 
(71%), On MRI it is difficult to differentiate tumor cells 
in scar tissue[58]. In a recent multicentric evaluation of  
MRI post neoadjuvant chemoradiotherapy (MERRION) 
found limited use of  MRI post therapy[59]. In a small se-
ries of  16 patients with locally advanced cancer MRI be-
fore and after LCRT (MRI 1 and MRI 2) were compared 
to final histology. The accuracies of  both MRI before 
and after radiotherapy were moderate, with no additional 
value of  MRI after radiotherapy. They concluded that 
morphological assessment of  pelvic MRI after preopera-
tive radiotherapy does not provide any significant new 
information about tumor extent in patients with locally 
advanced rectal cancer[60]. Similarly, in another study, au-
thors felt that accuracy of  MRI 2 in distinguishing tumor 
delineation might be difficult due to fibrosis[61]. Post 
treatment MRI is a poor predictor of  final histology and 
should not be relied upon to guide the extent of  surgical 
resection. Larsen et al[62] felt that to achieve R0 resection, 
optimal surgery should be based on pre-treatment MRI. 
The study has initiated a new approach to histopathologi-
cal classification of  the removed specimen where they 
introduce a MRI assisted technique for investigating the 
areas at risk outside the mesorectal fascia in the speci-
men[62]. Kang et al[63] concluded that the tumor volume re-
duction ratio was not significantly associated with T and 
N downstaging. MRI is unable to detect the majority of  
patients who have a complete histopathological response 
as MRI appearances of  ypT0 tumours are heteroge-
neous[64].
There is little consensus on the use of  MRI after 
LCRT. Martellucci et al[65] suggested against restaging with 
MRI and recommended TRUS. They found that regard-
ing the depth of  invasion after treatment, TRUS agreed 
Figure 6  (A) Pre-chemoradiotherapy and (B) postchemoradiotherapy 
status. Arrows point to tumor along left lateral wall tumor which is mildly hy-
perintense in A that has become darkly hypointense in B indicating response 
(fibrosis). 
B
A Table 4  Post long course chemoradiotherapy magnetic 
resonance imaging 2-Parameters are assessed on post 





Height of tumor from anal verge
Length of tumor 
Tumor stage 




Distance to potential CRM
Depth of maximum extramural spread 
(distance from outer edge of muscularis propria) 
tumor and fibrosis separately
Extramural venous invasion
MRI tumor regression grade, Grade Ⅴ: No response (same as original 
tumor); Grade Ⅳ: Slight response (litte area of fibrosis/mucin, mostly 
tumor); Grade Ⅲ: Moderate response (more than 50% fibrosis, mucin 
but mostly tumor); Grade Ⅱ: Good response (dense fibrosis, no obvious 
residual tumor); Grade Ⅰ: Radiological complete response (no evidence of 
ever treated tumor); CRM: Circumferential resection margin. 
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with histopathology in 25/37 patients (67.5%), CT 
agreed in 22/37 cases (59.5%), and MRI in 12/20 cases 
(60%). They therefore suggested limiting the use of  MRI 
for restaging to selected cases. There however is uniform 
consensus on current guidelines, which advocate remov-
ing areas of  fibrosis on MRI 2, as they could harbor tu-
mor cells.
Even in United Kingdom, ACPGBI guidelines do not 
enforce MRI 2[8] prior to surgery. Ultimately it would be 
a joint decision by individual MDT as there seems to be 
no uniform consensus across the board. In low resource 
economies MRI 2 may be performed only in selected 
cases for locally advanced unresectable cases to plan op-
erability, extent of  resection or consideration of  more 
non-cross resistant chemotherapy prior to surgery.
Timing of  MRI 2: There remains some controversy 
regarding the optimum time for imaging prior to surgery 
after the chemoradiotherapy treatment has been complet-
ed. As surgery is planned for approximately 6-8 wk after 
the final chemoradiotherapy treatment, the MRI needs to 
be performed during this time, too early and the oncolo-
gists will argue that the chemoradiotherapy will still be 
having effects and potentially decrease the tumour size 
further; therefore the closer to surgery the better. Many 
centres aim for approximately 1 mo after LCRT to enable 
the surgery to be planned/organised.
MRI for surveillance
Surgical treatment offers the best prospect of  survival for 
patients with recurrent colorectal cancer. Unfortunately, 
most local recurrences are diagnosed at an advanced 
(unresectable) stage, when traditional follow-up methods 
are used. The impact of  MRI surveillance on the early 
diagnosis of  local recurrences has been evaluated by Titu 
et al[66] In this unique study, 226 patients who underwent 
curative surgery for rectal and left-sided colon tumors 
were included in a program of  surveillance using pelvic 
MRI in addition to standard follow-up protocol. Twenty-
six (13%) local recurrences were identified. These were 
then analyzed based on mode of  diagnosis, resectability, 
and overall survival. Recurrent pelvic cancer was diag-
nosed by MRI with a 87% sensitivity and 86% specificity. 
In 19 (63%) cases, CEA was abnormally elevated, and 9 
patients (30%) were symptomatic. Surgical resection was 
possible in only 6 patients (20%). There was no differ-
ence between MRI and conventional follow-up tests in 
their ability to detect cases suitable for surgery. Hence 
they concluded, pelvic surveillance by MRI is not justified 
as part of  the routine follow-up after a curative resection 
for colorectal cancer and should be reserved for selec-
tively imaging patients with clinical, colonoscopic, and/or 
biochemical suspicion of  recurrent disease[66].
Functional outcome: MRI pelvis may predict functional 
outcome in patients undergoing anterior resection. In a 
small series of  patients undergoing anterior resection, 
How et al[67] evaluated functional outcome and co-related 
it with preoperative MRI sphincter morphology and 
anal manometry. They found only puborectalis thick-
ness showed a significant (P = 0.01) relationship with the 
number of  adverse symptoms suffered postoperatively[67].
MRI in recurrent cancers
MRI scans of  pelvis are mandatory for selection for 
exenterative surgeryfor recurrent cancers, as CRM co-
relates with survival. In primary cancers, assessing the 
preservation of  fat plane can be used to predict inva-
sion. However this is difficult in post-operative/post-
radiotherapy pelvis, where fat planes are often grossly 
distorted or absent. Pelvic oncology unit in Leeds con-
sider definite invasion in three specific circumstances on 
MRI: (1) when tumour tissue is clearly seen to invade 
or destroy adjacent anatomy; (2) when signal change in 
adjacent tissue is comparable with the signal intensity of  
the recurrent tumour; or (3) where muscle enlargement 
is evident. In their experience when patients are assessed 
between 21 and 48 mo post-primary surgery, muscle 
enlargement seen on MRI is related to recurrence rather 
than haematoma/inflammatory changes[68].
MRI directed MDT: MRI directed MDT improves out-
come and is mandatory for recognition as a cancer cen-
tre. In 2006, Burton et al[69] compared CRM involvement 
of  rectal cancer patients who were operated with/with-
out MDT discussion and found low CRM involvement in 
patients discussed at MDT. This opinion however is not 
uniform. Review By Danish MDT team found increased 
detection of  metachronous cancers through MDT but no 
difference in overall survival. Similar results were shown 
by Department of  Health care policy, Harvard Medical 
school[70,71].
CLINICAL APPLICATION OF MRI FOR THE 
SURGEON
T1/T2 cancer. MRI can’t differentiate, hence need en-
dorectal usg to identify T1 cancers. Theses may be candi-
dates for local excision (transanal or TEO) (Figure 4).
T3 minimal (no CRM involvement) can go for sur-
gery either per primum or after shortcourse radiotherapy 
(Figure 2).
T3/N0, + (Figures 3, 7 and 8) with circumferential 
margin involvement and T4 tumors (Figure 9) are treated 
with LCRT and reassesses with MRI 2.
All rectal cancer with pelvic side wall nodes needs to 
undergo LCRT as this leads to improved survival and 
avoids need for lateral pelvic node dissection (Figure 8).
All low rectal cancers (5 cm from anal verge) are as-
sesses with coronal images of  MRI T2 sequences, to see 
involvement of  intersphincteric plane and extension to 
levator ani: (1) those tumors free from intersphincteric 
plane and more than 1 mm from levator plate can be 
subjected to intersphincteric dissection and sphincter 
saving procedures (Figure 10A); (2) tumors involving 
intersphincteric space and external sphincters undergo 
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standard APER (Figure 10B); and (3) tumors involving 
levators need extralevator APER (Figure 11).
DISCUSSION
One of  the most important factors that governs the suc-
cess of  TME surgery is the relationship of  tumour to 
the CRM. Tumour involvement of  the CRM in patients 
undergoing TME surgery is related to poor survival and 
local recurrence. Tumor relation to CRM on MRI (pre-
dicted CRM) helps in planning preoperative LCRT in 
selected cases. MRI may help plan plane of  resection for 
low rectal tumors and may decreases CRM involvement 
and ultimate outcome (LOREC project).
While not in line with NCCN (National compre-
hensive cancer Network) guidelines, it helps avoid ra-
diotherapy for T3 patients where predicted CRM is not 
threatened. This will mitigate radiotherapy related com-
plications and improve bowel function. In addition, MRI 
will identify tumours exhibiting other poor prognostic 
features, namely, extramural spread > 5 mm, extramu-
ral venous invasion by tumour, nodal involvement, and 
peritoneal infiltration who may be candidates for trials re-
garding intensive chemotherapy/biological therapy along 
with radiotherapy to improve DFS/OS/LR.
For advanced tumors (Non-resectable) on MRI, tar-
geted preoperative therapy may not only reduce the size 
of  the primary tumour and render potentially unresect-
able tumour resectable. This would also enable patients 
at high risk of  systemic failure to benefit from intensive 
combined modality therapy aimed at eliminating micro-
metastatic disease[72]. The Role of  MRI post LCRT is 
uncertain but is often used in selected centres planning to 
offer sphincter preservation based on tumor response.
Figure 9  T4 lesion rectum involving prostate. 
Figure 8  T3 tumor with lateral pelvic nodes. Axial T2W magnetic resonance 
imaging shows a large right lateral pelvic wall node (arrowhead). Short arrow 
shows perirectal node. The primary rectal tumor (asterisk) is seen extending 
into left mesorectal fat upto the mesorectal fascia (long arrow). 
* *
*
Figure 7  T3 tumor with spiculation reaching mesorectal fascia. Peritumor-
al fibrosis. T2W axial magnetic resonance imaging shows rectal tumor along 
anterior wall with spiculations (small white arrows) into the perirectal fat. The 
spiculation reaches up to mesorectal fascia (black arrow) at 12’ o’clock position 
(long white arrow) causing focal fascia retraction.
Figure 10  Coronal section T2 weighted magnetic resonance imaging to 
see level of tumor for planning surgery. A and B show tumor (asterisk) along 
the left lateral wall, that reaches up to the internal sphincter (short white arrows) 
in B, but spares it in A. The uninvolved external sphincter (darkly hypointense) 
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CONCLUSION
MRI should be mandatory in planning radical surgery for 
rectal cancer. This improve R0 resection rates, decreases 
local recurrences with improved oncological outcomes. 
There is uncertainty over the role of  MRI post LCRT. 
While MRI directed MDT has shown improved outcome 
in most studies, this however is debatable. The role of  
MRI in early rectal cancer seems to be limited, and needs 
complimentary endorectal ultrasound.
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